These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 22414425)
1. Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin α₂β₁ receptor. Knudsen NØ; Schiffelers RM; Jorgensen L; Hansen J; Frokjaer S; Foged C Int J Pharm; 2012 May; 428(1-2):171-7. PubMed ID: 22414425 [TBL] [Abstract][Full Text] [Related]
2. A stabilized peptide ligand for multifunctional glioma targeted drug delivery. Ying M; Shen Q; Zhan C; Wei X; Gao J; Xie C; Yao B; Lu W J Control Release; 2016 Dec; 243():86-98. PubMed ID: 27693752 [TBL] [Abstract][Full Text] [Related]
3. PR_b-targeted PEGylated liposomes for prostate cancer therapy. Demirgöz D; Garg A; Kokkoli E Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096 [TBL] [Abstract][Full Text] [Related]
4. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H J Control Release; 2011 Jul; 153(2):141-8. PubMed ID: 21447361 [TBL] [Abstract][Full Text] [Related]
5. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. Chen Z; Deng J; Zhao Y; Tao T Int J Nanomedicine; 2012; 7():3803-11. PubMed ID: 22888235 [TBL] [Abstract][Full Text] [Related]
6. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Garg A; Tisdale AW; Haidari E; Kokkoli E Int J Pharm; 2009 Jan; 366(1-2):201-10. PubMed ID: 18835580 [TBL] [Abstract][Full Text] [Related]
7. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970 [TBL] [Abstract][Full Text] [Related]
8. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Amin M; Badiee A; Jaafari MR Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663 [TBL] [Abstract][Full Text] [Related]
9. Tumor-targeted liposomal drug delivery mediated by a diseleno bond-stabilized cyclic peptide. Li C; Wang Y; Zhang X; Deng L; Zhang Y; Chen Z Int J Nanomedicine; 2013; 8():1051-62. PubMed ID: 23515368 [TBL] [Abstract][Full Text] [Related]
10. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells. Shroff K; Kokkoli E Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611 [TBL] [Abstract][Full Text] [Related]
11. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity. Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852 [TBL] [Abstract][Full Text] [Related]
12. Effect of PEG pairing on the efficiency of cancer-targeting liposomes. Saw PE; Park J; Lee E; Ahn S; Lee J; Kim H; Kim J; Choi M; Farokhzad OC; Jon S Theranostics; 2015; 5(7):746-54. PubMed ID: 25897339 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: Application of cyclic RGD peptide. Kato N; Sato T; Fuchigami Y; Suga T; Geng L; Tsurumaru M; Hagimori M; Mukai H; Kawakami S Eur J Pharm Sci; 2022 Sep; 176():106239. PubMed ID: 35714942 [TBL] [Abstract][Full Text] [Related]
15. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801 [TBL] [Abstract][Full Text] [Related]
16. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123 [TBL] [Abstract][Full Text] [Related]
17. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor. Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321 [TBL] [Abstract][Full Text] [Related]
18. Dual-ligand α Levine RM; Kokkoli E J Control Release; 2017 Apr; 251():24-36. PubMed ID: 28215671 [TBL] [Abstract][Full Text] [Related]
19. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery. Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902 [TBL] [Abstract][Full Text] [Related]
20. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes. Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]